<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045756</url>
  </required_header>
  <id_info>
    <org_study_id>R.S. 68.19</org_study_id>
    <nct_id>NCT04045756</nct_id>
  </id_info>
  <brief_title>Focal Laser Ablation for the Treatment of Focal Low-Intermediate Risk Prostate Cancer</brief_title>
  <official_title>Short-term Efficacy of Transperineal Laser Ablation (TPLA) With Image Fusion and Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer: Interventional Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Short-term Efficacy of Transperineal Laser Ablation (TPLA) with Image Fusion and&#xD;
      Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer. It is an&#xD;
      interventional pilot study. The clinical evaluation will be carried out at different times as&#xD;
      follows:&#xD;
&#xD;
      Time 0: recruitment and eligibility assessment (patient selection) Time 1: interview, signing&#xD;
      of informed consent and enrollment Time 2: FLA treatment and control with multiparametric MRI&#xD;
      of the post-procedural prostate.&#xD;
&#xD;
      Time 3-4-5-6: follow up to 1 (T3), 6 (T4), 12 (T5) and 24 (T6) months from the procedure.&#xD;
&#xD;
      The primary objective of the study is to evaluate the short-term (2 years) efficacy of FLA&#xD;
      treatment of low-intermediate risk prostate cancer Secondary objective is to investigate&#xD;
      multiparametric prostate MRI as a follow-up diagnostic investigation, evaluating possible&#xD;
      glandular morphostructural changes and their correlation with clinical data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Short-term Efficacy of Transperineal Laser Ablation (TPLA) With Image Fusion and&#xD;
      Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer. It is an&#xD;
      interventional pilot study.&#xD;
&#xD;
      The recruitment and evaluation of eligibility will be done by the Multidisciplinary Neoplasms&#xD;
      Group of the Uro-Genital System, already operating within the Tor Vergata Polyclinic&#xD;
      Foundation and formed by the following Operating Units:&#xD;
&#xD;
      UOSD Urology, UOC Diagnostic Imaging, UOC Medical Oncology, UOC Radiotherapy, UOSD&#xD;
      Pathological Anatomy, UOC Nuclear Medicine. The Multidisciplinary Group will propose and&#xD;
      evaluate patients that can be recruited based on inclusion and exclusion criteria. The&#xD;
      patient considered eligible for the study will be adequately informed by the UOSD Urology /&#xD;
      UOC Diagnostic Imaging regarding the therapeutic possibilities for the specific disease&#xD;
      stage.&#xD;
&#xD;
      If the patient expresses an interest in participating in the study, he will be given informed&#xD;
      consent.&#xD;
&#xD;
      Once the informed consent has been signed, the patient will be considered enrolled in the&#xD;
      study.&#xD;
&#xD;
      Pre-procedural evaluation&#xD;
&#xD;
      Pre-treatment clinical-instrumental-blood chemistry tests include:&#xD;
&#xD;
        -  Electrocardiogram&#xD;
&#xD;
        -  Complete blood count, blood ureanitrogen (BUN), creatinine, sodium, potassium,&#xD;
           coagulation tests&#xD;
&#xD;
        -  Urine examination and urine culture&#xD;
&#xD;
        -  Evaluation of the post-voiding residue&#xD;
&#xD;
        -  Uroflowmetry (if IPSS&gt; 7)&#xD;
&#xD;
      Questionnaires:&#xD;
&#xD;
        -  IPSS-QoL&#xD;
&#xD;
        -  IIEF&#xD;
&#xD;
      Focal laser ablation treatment (FLA):&#xD;
&#xD;
      The treatments will be performed by the Diagnostic Imaging team, on a Day Hospital basis,&#xD;
      using the combined Echolaser XVG system (Elesta s.r.l - Calenzano (FI)).&#xD;
&#xD;
      The EchoLaser Therapy is a micro-invasive percutaneous procedure that uses the laser light&#xD;
      transmitted through applicators (optical fibers) for a few minutes, causing the affected&#xD;
      tissue to warm up until it is irreversibly damaged in &quot;situ&quot;, without the need to remove it.&#xD;
&#xD;
      All this thanks to the combined action of an increase in the local temperature and the&#xD;
      exposure time. The interaction of laser radiation with a wavelength of 1064nm (in the range&#xD;
      of the therapeutic window) is excellent, with low radiation absorption and excellent light&#xD;
      penetration. The laser light is conveyed from the source to the fabric through extremely&#xD;
      flexible, small-caliber (300 micron diameter) flat-tip quartz optical fibers, introduced&#xD;
      percutaneously by thin needles (21 Gauge).&#xD;
&#xD;
      The EchoLaser Therapy, through flat-tipped fibers, produces an ellipsoidal coagulation area&#xD;
      (an area where the tissue has irreversible damage). A possible multi-fiber approach can&#xD;
      extend the coagulation area.&#xD;
&#xD;
      The EchoLaser Therapy can be performed under ultrasound guidance for real-time monitoring of&#xD;
      the correct positioning of the laser light applicators and the effective extension of the&#xD;
      damage to the tumor lesion.&#xD;
&#xD;
      The procedure will be performed with a patient in a lithotomy position and in safe conditions&#xD;
      according to the current legislation for treatments with laser systems (such as protective&#xD;
      glasses).&#xD;
&#xD;
      Treatment includes local anesthesia of the perineal region, under ultrasound guidance. At the&#xD;
      discretion of the medical team, intravenous sedation can be performed.&#xD;
&#xD;
      1-2 spinal needles 21G will be inserted into the intralesional site by ultrasound-guided&#xD;
      transperineal route after MRI / TRUS image fusion. In each needle a 300 micron optical fiber&#xD;
      will be inserted (Elesta s.r.l., Calenzano (FI)). For each lighting, for about 6 minutes, a&#xD;
      maximum energy of 1800 J per fiber will be delivered, with a power of 2-5 Watts. If&#xD;
      necessary, the needle and fiber will be retracted for about 1 cm (&quot;pull-back&quot;). Further&#xD;
      lighting will follow, with delivery and duration and power equal to the previous one.&#xD;
&#xD;
      Immediately after the procedure, the patient will be asked to complete the VAS score for the&#xD;
      assessment of pain felt during the procedure.&#xD;
&#xD;
      Complications: The potential complications of the FLA technique are:&#xD;
&#xD;
        -  Peri-operative: perineal and hypogastric pain, perineal hematoma, hematuria, acute&#xD;
           urinary retention, fever, dysuria&#xD;
&#xD;
        -  Postoperative: perineal pain, LUTS, persistent hematuria, hematospermia, erectile&#xD;
           dysfunction, urinary incontinence Complications will be investigated prospectively using&#xD;
           the Clavien-Dindo classification&#xD;
&#xD;
      Follow-up: The clinical evaluation will be carried out at different times:&#xD;
&#xD;
      Post procedural follow up A multi-parametric prostate MRI will be performed immediately after&#xD;
      the treatment. At the end of the treatment the resumption of spontaneous diuresis will be&#xD;
      checked and in the case of acute urinary retention / clinically significant hematuria a&#xD;
      bladder catheter will be inserted.&#xD;
&#xD;
      An oral cortisone drug (Deflazacort 30 mg) or other anti-edema therapy will be prescribed if&#xD;
      specifically contraindicated by the patient.&#xD;
&#xD;
      Any complications will be recorded according to the Clavien-Dindo classification The patient&#xD;
      will be discharged with antibiotic therapy, pain relief when needed and gastroprotective for&#xD;
      5-7 days.&#xD;
&#xD;
      Patients will receive a telephone contact to use to communicate any post-operative&#xD;
      emergencies.&#xD;
&#xD;
      Post-discharge follow-up The specialist follow-up visit to 1 (T3), 6 (T4), 12 (T5) and 24&#xD;
      (T6) months from the procedure will be conducted by the UOSD Urology.&#xD;
&#xD;
      Any reported complications will be recorded according to the Clavien-Dindo classification.&#xD;
&#xD;
      The patient will be asked to complete the IPSS-QoL and IIEF questionnaires and will view the&#xD;
      total serum PSA (T4-T5-T6).&#xD;
&#xD;
      Multi-parametric prostate MRI will be performed at T4-T6. Transperineal prostatic control&#xD;
      biopsy will be performed with fusion target (ablated zone) and systematic technique (T4-T6).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Anticipated">August 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Cancer control defined as the percentage of patients with disease free survival according to the pathological MR-guided biopsy results in a 5 year period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Complications of prostate Laser Ablation on the Treatment of Focal Low-Intermediate Risk Prostate Cancer by use of mp-MRI.</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of the post-procedural complications by mpMRI. In particular damage to neuro-vascular bundles, seminal vescicles and peri-prostatic fat will be checked.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of mpMRI in correlation with biopsy in order to establish positive/negative predictive diagnostic values of MRI in residual/relapsing tumors</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of multi-parametric MRI of the prostate and evaluate the response to focal laser ablation treatment for focal low-intermediate prostate cancer by biopsy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ECHOLASER X4 Socratelite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)</intervention_name>
    <description>The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.</description>
    <arm_group_label>ECHOLASER X4 Socratelite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Over 45 years old&#xD;
&#xD;
          -  Prostate cancer identified after prostatic biopsy with fusion of images with target&#xD;
             and systematic samples (&gt; 12)&#xD;
&#xD;
          -  Intermediate progression risk (Gleason Score 3 + 4 or 4 + 3; PSA &lt;15 ng / ml; clinical&#xD;
             stage T1-T2a)&#xD;
&#xD;
          -  Low risk of progression (Gleason score 3 + 3) only in patients who wish to leave or&#xD;
             who refuse the active surveillance protocol and who refuse validated treatments for&#xD;
             the treatment of organo-confined prostate cancer: radical surgery and / or&#xD;
             radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prostate cancer Gleason Score&gt; = 4 + 4.&#xD;
&#xD;
          -  Clinical stage&gt; T2a&#xD;
&#xD;
          -  PSA&gt; 15 ng / ml&#xD;
&#xD;
          -  Presence of metastases from prostate lymph node, bone or visceral carcinoma detected&#xD;
             by bone scintigraphy, total body CT or PET-CT&#xD;
&#xD;
          -  Serious coagulation disorders not correctable&#xD;
&#xD;
          -  Unavailable or replaceable anticoagulant and / or antiplatelet therapy&#xD;
&#xD;
          -  Inadequate compliance&#xD;
&#xD;
          -  Presence of pacemakers&#xD;
&#xD;
          -  Contraindications to MRI (claustrophobia, ear implants, metal prostheses)&#xD;
&#xD;
          -  Paramagnetic contrast agent allergy&#xD;
&#xD;
          -  Acute and / or chronic renal failure (GFR &lt;50 mL / min and serum creatinine&gt; 1.5 mg /&#xD;
             dl)&#xD;
&#xD;
          -  Tumor volume &lt;15 ml measured on MRI&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guglielmo Manenti, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Tor Vergata</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guglielmo Manenti, MD PhD</last_name>
    <phone>39 0620902281</phone>
    <email>gu.manenti@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvatore Marsico, MD PhD</last_name>
    <email>salvatore.marsico@hotmail.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico Tor Vergata (PTV) Foundation: Department di Biomedicine and Prevention</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guglielmo Manenti, MD PhD</last_name>
      <phone>+39 0620902281</phone>
      <email>gu.manenti@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Roberto Floris, MD PhD</last_name>
      <phone>+39 0620902400</phone>
      <email>roberto.floris@uniroma2.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella CM. Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study. Cardiovasc Intervent Radiol. 2017 Sep;40(9):1440-1446. doi: 10.1007/s00270-017-1662-9. Epub 2017 May 4.</citation>
    <PMID>28474112</PMID>
  </reference>
  <reference>
    <citation>Lindner U, Lawrentschuk N, Trachtenberg J. Image guidance for focal therapy of prostate cancer. World J Urol. 2010 Dec;28(6):727-34. doi: 10.1007/s00345-010-0604-9. Epub 2010 Oct 21. Review.</citation>
    <PMID>20963422</PMID>
  </reference>
  <reference>
    <citation>Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M, Wilson BC, Fenster A, Trachtenberg J. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009 Oct;182(4):1371-7. doi: 10.1016/j.juro.2009.06.035. Epub 2009 Aug 14.</citation>
    <PMID>19683262</PMID>
  </reference>
  <reference>
    <citation>Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG; Society of Interventional Radiology Technology Assessment Committee. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005 Jun;16(6):765-78.</citation>
    <PMID>15947040</PMID>
  </reference>
  <reference>
    <citation>Bremer C, Kreft G, Roggan A, Filler T, Reimer P. Ex vivo evaluation of novel miniaturized laser-induced interstitial thermotherapy applicators for effective small-volume tissue ablation. Invest Radiol. 2001 Jun;36(6):327-34.</citation>
    <PMID>11410753</PMID>
  </reference>
  <reference>
    <citation>Costello AJ, Johnson DE, Bolton DM. Nd:YAG laser ablation of the prostate as a treatment for benign prostatic hypertrophy. Lasers Surg Med. 1992;12(2):121-4.</citation>
    <PMID>1374142</PMID>
  </reference>
  <reference>
    <citation>Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener S. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun;267(3):932-40. doi: 10.1148/radiol.13121652. Epub 2013 Feb 25.</citation>
    <PMID>23440319</PMID>
  </reference>
  <reference>
    <citation>van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Oct;37(10):2147-2153. doi: 10.1007/s00345-019-02636-7. Epub 2019 Jan 22.</citation>
    <PMID>30671638</PMID>
  </reference>
  <reference>
    <citation>Walser E, Nance A, Ynalvez L, Yong S, Aoughsten JS, Eyzaguirre EJ, Williams SB. Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease. J Vasc Interv Radiol. 2019 Mar;30(3):401-409.e2. doi: 10.1016/j.jvir.2018.09.016.</citation>
    <PMID>30819483</PMID>
  </reference>
  <reference>
    <citation>Lepor H. Vascular targeted photodynamic therapy for localized prostate cancer. Rev Urol. 2008 Fall;10(4):254-61.</citation>
    <PMID>19145269</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>December 14, 2019</last_update_submitted>
  <last_update_submitted_qc>December 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>Guglielmo Manenti</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>laser ablation</keyword>
  <keyword>mpMRI</keyword>
  <keyword>interventional radiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Create an international registry to assess long-term effectiveness of transperineal laser ablation for focal prostate cancer, to assess functional outcomes, to assess safety, to determine baseline patient characteristics, to collect information on possible differences between centres applying treatment of transperineal laser ablation and to explore the optimal treatment indications and possible limitations. It an international prospective observational registry in which data is recorded of patients who are treated with transperineal laser ablation for low-intermediate risk focal prostate cancer.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>This registry will be open for inclusion for five years. Since individual patients will have a follow-up of five years, the total study duration will be 10 years.</ipd_time_frame>
    <ipd_access_criteria>Every accredited centre that performs TPLA procedures, wants to participate and signs the regulatory document and obtains ethical committee approval can participate</ipd_access_criteria>
    <ipd_url>https://www.flaprostate.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT04045756/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT04045756/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

